AIB1:ERα Transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3305-3315

  O'Hara, Jane ^a   Vareslija, Damir ^a   McBryan, Jean ^a   Bane, Fiona ^a   Tibbitts, Paul ^a   Byrne, Christopher ^a   Conroy, Ronán M ^a   Hao, Yuan ^b   Gaora, Peadar Ó ^b   Hill, Arnold D K ^a   McIlroy, Marie ^a   Young, Leonie S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE INHIBITOR; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; LETROZOLE; MYC PROTEIN; PROTEIN FOS; PROTEIN PS2; STEROID; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE CONTROL; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE MICROARRAY; TRANSCRIPTION INITIATION;

ANDROSTENEDIONE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; NEOPLASM RECURRENCE, LOCAL; NITRILES; NUCLEAR RECEPTOR COACTIVATOR 3; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC; TRIAZOLES; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84862536956     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3300     Document Type: Article

References (36)

1. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33. (Pubitemid 351519691)
2. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009;15:2098-106.
3. Salmon-Divon M, Dvinge H, Tammoja K, Bertone P. PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci. BMC Bioinformatics 2010;11:415.
4. Xu J,WuRC, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009;9:615-30.
5. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1/SRC-3 de ficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004;64:1875-85. (Pubitemid 38428714)
6. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74. (Pubitemid 39222039)
7. Chen S. An "omics" approach to determine the mechanisms of acquired aromatase inhibitor resistance. OMICS 2011;15:347-52.
8. Martin LA, Ghazoui Z, Weigel MT, Pancholi S, Dunbier A, Johnston S, et al. An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 2011;76:772-6.
9. Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res 2001;7:4360s-8s; discussion 4411s-2s.
10. Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 2011;76:750-2.
11. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s. (Pubitemid 40111098)
12. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
13. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 2012;72:548-59.
14. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, et al. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 2008;630:19-34.
15. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, et al. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 2002;193:29-42. (Pubitemid 34823605)
16. Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 2005;12 Suppl 1:S75-84. (Pubitemid 41395415)
17. Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res 2006;12:1008s-12s. (Pubitemid 43259836)
18. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164-74. (Pubitemid 28513702)
19. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008;27:3021-31. (Pubitemid 351668011)
20. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y, et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005;11:2111-22. (Pubitemid 40490167)
21. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006;1:179-85.
22. Lanz RB, Bulynko Y, Malovannaya A, Labhart P, Wang L, Li W, et al. Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol 2011;24:859-72.
23. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN. ChIP-Seq of ER-alpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009;28:1418-28.
24. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptoralpha and estrogen receptor in breast cancer. Genes Dev 2010;24: 171-82.
25. Zhu LJ, Pages H, Gazin C, Lawson N, Lin S, Lapointe D, et al. ChIPpeakAnno: Batch annotation of the peaks identified from either ChIP-seq or ChIP-chip experiments. R package version 1.8.0. [cited 2011]. Available from: http://www.bioconductor.org/packages/2.9/ bioc/html/ChIPpeakAnno.html.
26. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
27. Schwartz S, Elnitski L, Li M, Weirauch M, Riemer C, Smit A, et al. MultiPipMaker and supporting tools: alignments and analysis of multiple genomic DNA sequences. Nucleic Acids Res 2003;31:3518-24. (Pubitemid 37442189)
28. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007;23:257-8. (Pubitemid 46189622)
29. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61. (Pubitemid 36395255)
30. Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer 2006;13:1135-45. (Pubitemid 46212568)
31. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009;100:2028-33.
32. Carlomagno T. Ligand-target interactions: what can we learn from NMR? Annu Rev Biophys Biomol Struct 2005;34:245-66. (Pubitemid 40847725)
33. Altiok N, Koyuturk M, Altiok S. JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. Breast Cancer Res Treat 2007;105:247-54. (Pubitemid 47596440)
34. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
35. Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, et al. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 2011;286:8117-27.
36. Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol 2010;30:3111-25.